What is the current Capecitabine Market size?

The Capecitabine Market is projected to register a CAGR of 5.5% during the forecast period (2024-2029) Read More

Who are the key players in Capecitabine Market?

Teva Pharmaceuticals, Inc, F. Hoffmann-La Roche AG (Genentech, Inc.), Mylan N.V., Hikma Pharmaceuticals PLC and Cipla Inc. are the major companies operating in the Capecitabine Market. Read More

Which is the fastest growing region in Capecitabine Market?

Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029). Read More

Which region has the biggest share in Capecitabine Market?

In 2024, the North America accounts for the largest market share in Capecitabine Market. Read More

What years does this Capecitabine Market cover?

The report covers the Capecitabine Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Capecitabine Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029. Read More

Capecitabine Market Share

Statistics for the 2023 & 2024 Capecitabine market share, created by Mordor Intelligence™ Industry Reports. Capecitabine share report includes a market forecast to 2029 and historical overview. Get a sample of this industry share analysis as a free report PDF download.

Market Share of Capecitabine Industry

The global capecitabine market is moderately competitive and consists of several major players. Few of the prominent players currently dominating the market are applying various strategies like acquiring the products or other companies to consolidate their market positions across the globe and while others are launching generic products. For example, in April 2019, Armas Pharmaceuticals, Inc launched a generic version of Roches's Xeloda, a capecitabine product. Such product launches are expected to propel the market growth. Some of the companies which are currently dominating the market are Cipla Inc., Teva Pharmaceuticals USA Inc, F. Hoffmann-La Roche AG (Genentech, Inc.), Mylan N.V., and Hikma Pharmaceuticals PLC.